Kite gets rights to Sangamo's zinc finger nuclease platform; could pay $3bn
Gilead Sciences Inc. division Kite Pharma Inc. licensed exclusive rights to use Sangamo Therapeutics Inc.’s zinc finger nuclease (ZFN) technology for the development of new cell therapies for cancer.
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Tools
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.